Nged allografts survival. imDC prolonged islet allograft survival when incubated in a special bioreactor with continuous rotation in culture media, and even appeared to induceInfusion Tol-DC Prolongs Islet Allograft SurvivalTable 2. Characteristics of included studies.NO. StudyAnimal model(Mice/Rat)Tol-DC(Number) (total number)Controls C1 COutcomes O1 O2 O3 O4 ODC(R/D)PS 1145 Untreated Negative SUR A1 * (D)H-2 Stepkowsk(2006)bMLR CK /Treg CTL Y / R-DC(R)H-d(T)H-kBioreactorimDC(Balb/c) (5) Bioreactor-imDC (Balb/cStat42/2) (5)!.150d / .150dTotleMHC total Dimethylenastron chemical information mismatch: n = 1 (R)RT-1a (T)RT-1nMonotherapy: n = 0 Combination: n =R-DC:n = 1 D-DC:n =BOlakunle(2001)11 (D)RT-1uP5-BMDC(10`6,i.v.) (5) P5-BMDC+ALS (2*10`6,i.v.) (5) P5-BMDC(2*10`6,i.v.) (4) P5-BMDC+ALS(10`6,i.t.) (11) P5-thymic DC(5*10`6,i.v.) (4) P5-thymic DC+ALS (5*10`6,i.v.) (4)!q .200d q .200d q .200dY///R-DCBAli(2000)(D)RT-1u(R)RT-1a (D)RT-1l(T)RT-1n (T)RT-1nP5-DC+ALS(-) (5) P5-DC+ALS(0.5 ml) (5)!!q qY///R-DCBOluwole(1995)13 (R)RT-1uD-Ag+DC(R) (3) D-Ag+DC(D) (4)!!q -Y///R/D-DCTotleMHC total mismatch: n =b dMonotherapy: n = 3 Combination: n =R-DC:n = 3 D-DC:n =C1 C2 CYang(2008)2 Zhu(2008)(R)H-(D)H-CTLA-4Ig-DC(8) IL10-DC(8) (T)H-2k D2SC/1-CTLA4-Ig (10) D2SC/1-CTLA4-Ig (additional injection)! ! !! ! !q q q -Y Y YTH2 TH2 // / // / // R-DC D-DC(R)H-2b(D)H-2d (D)H-2dO’Rourke(2000)4 (R)H-2bCLi(2010)//rAd-DCR3-DC rAd-GAD65/DCR3-DC!!q q///Y/TotleMHC total mismatch: n =b dMonotherapy: n = 4 Combination: n =R-DC:n = 1 D-DC:n =D1 Hauben(2008)(D)H-(R)H-mDC-VAF347 (17) imDC+VAF347 (19) mDC (14) imDC (18)!!q -YTHY/R-DCTotleMHC total mismatch: n = 1 (D)H-2dMonotherapy: n = 1 Combination: n =R-DC:n = 1 D-DC:n =EHuang(2010)7 (R)H-2bR-KSC+D-DC R-KSC+R-DC!!q -Y–/R/D-DCTotleMHC total mismatch: n = 1 (R)H-2b (D)H-2d (T)H-2kMonotherapy: n = 1 Combination: n = 0 CD4+imDC+anti-CD154Ab (6) CD4+imDC+antiCD154Ab+ anti-IL10R Ab(4) CD4+imDC (6) CD8+imDC (6) CD8+imDC+anti-CD154Ab (6)R-DC:n = 1 D-DC:n =FKim(2006)!!.120d Y .120d -THY/D-spleen DCFRastellini(1995)9 (R)H-2b(D)H-2kliver-imDC(10) spleen-imDC (4)!!q -Y///D-liver DCInfusion Tol-DC Prolongs Islet Allograft SurvivalTable 2. Cont.NO. StudyAnimal model(Mice/Rat)Tol-DC(Number) (total number)Controls C1 COutcomes O1 O2 O3 O4 ODC(R/D)Untreated Negative SUR F3 Chaib(1994)10 (D)RT-uMLR CK / /Treg CTL / / DspleenDC(R)RT-lDC+ALS (9) NPC+ALS (8)!-TotleMHC total mismatch: n =Monotherapy: n = 3 Combination: n =R-DC:n = 0 D-DC:n =A1: Immature dendritic cells (imDC) group. B1?: Allopeptide-pulsed group. C1?: Gene modification group. D1: Drug intervention group. E1: Mesenchymal stem cell (MSC) induction group. F1?: Other derived group. “ ” Articles did not report the sample size. “/” Articles did not report relevant information. “-” No difference between experiment group and control group. H-2b: C57. H-2d: BAL/C. H-2k: C3H. RT-1u: WF/WAG. RT-1a: ACI. RT-1n: BN. RT-1l: Lewis. D: Donor. R: Recipient. T: The third party. MHC: Major histocompatibility complex. BMDC: Bone marrow dendritic cell. Ag: Antigen. R-KSC: Host kidney-derived MSC. NPCs: Non-parenchymal cells. ALS: Anti-lymphocyte serum. P5: MHC Class I peptide five. 24195657 D-DC: Donor-derived DC. R-DC: Recipient-derived DC. SUR: Survival, “q” Prolongation. MLR: Mixed lymphocyte reaction, “Y” Successfully induced donor specific T cell hyporesponsiveness. CK: Cytokine. CTL: Cytotoxic T lymphocyte, “Y” Reduced cytotoxicity against allografts. Treg: Regulatory T cells, “Y” Successfully induced Treg. doi:10.1371/journal.pon.Nged allografts survival. imDC prolonged islet allograft survival when incubated in a special bioreactor with continuous rotation in culture media, and even appeared to induceInfusion Tol-DC Prolongs Islet Allograft SurvivalTable 2. Characteristics of included studies.NO. StudyAnimal model(Mice/Rat)Tol-DC(Number) (total number)Controls C1 COutcomes O1 O2 O3 O4 ODC(R/D)Untreated Negative SUR A1 * (D)H-2 Stepkowsk(2006)bMLR CK /Treg CTL Y / R-DC(R)H-d(T)H-kBioreactorimDC(Balb/c) (5) Bioreactor-imDC (Balb/cStat42/2) (5)!.150d / .150dTotleMHC total mismatch: n = 1 (R)RT-1a (T)RT-1nMonotherapy: n = 0 Combination: n =R-DC:n = 1 D-DC:n =BOlakunle(2001)11 (D)RT-1uP5-BMDC(10`6,i.v.) (5) P5-BMDC+ALS (2*10`6,i.v.) (5) P5-BMDC(2*10`6,i.v.) (4) P5-BMDC+ALS(10`6,i.t.) (11) P5-thymic DC(5*10`6,i.v.) (4) P5-thymic DC+ALS (5*10`6,i.v.) (4)!q .200d q .200d q .200dY///R-DCBAli(2000)(D)RT-1u(R)RT-1a (D)RT-1l(T)RT-1n (T)RT-1nP5-DC+ALS(-) (5) P5-DC+ALS(0.5 ml) (5)!!q qY///R-DCBOluwole(1995)13 (R)RT-1uD-Ag+DC(R) (3) D-Ag+DC(D) (4)!!q -Y///R/D-DCTotleMHC total mismatch: n =b dMonotherapy: n = 3 Combination: n =R-DC:n = 3 D-DC:n =C1 C2 CYang(2008)2 Zhu(2008)(R)H-(D)H-CTLA-4Ig-DC(8) IL10-DC(8) (T)H-2k D2SC/1-CTLA4-Ig (10) D2SC/1-CTLA4-Ig (additional injection)! ! !! ! !q q q -Y Y YTH2 TH2 // / // / // R-DC D-DC(R)H-2b(D)H-2d (D)H-2dO’Rourke(2000)4 (R)H-2bCLi(2010)//rAd-DCR3-DC rAd-GAD65/DCR3-DC!!q q///Y/TotleMHC total mismatch: n =b dMonotherapy: n = 4 Combination: n =R-DC:n = 1 D-DC:n =D1 Hauben(2008)(D)H-(R)H-mDC-VAF347 (17) imDC+VAF347 (19) mDC (14) imDC (18)!!q -YTHY/R-DCTotleMHC total mismatch: n = 1 (D)H-2dMonotherapy: n = 1 Combination: n =R-DC:n = 1 D-DC:n =EHuang(2010)7 (R)H-2bR-KSC+D-DC R-KSC+R-DC!!q -Y–/R/D-DCTotleMHC total mismatch: n = 1 (R)H-2b (D)H-2d (T)H-2kMonotherapy: n = 1 Combination: n = 0 CD4+imDC+anti-CD154Ab (6) CD4+imDC+antiCD154Ab+ anti-IL10R Ab(4) CD4+imDC (6) CD8+imDC (6) CD8+imDC+anti-CD154Ab (6)R-DC:n = 1 D-DC:n =FKim(2006)!!.120d Y .120d -THY/D-spleen DCFRastellini(1995)9 (R)H-2b(D)H-2kliver-imDC(10) spleen-imDC (4)!!q -Y///D-liver DCInfusion Tol-DC Prolongs Islet Allograft SurvivalTable 2. Cont.NO. StudyAnimal model(Mice/Rat)Tol-DC(Number) (total number)Controls C1 COutcomes O1 O2 O3 O4 ODC(R/D)Untreated Negative SUR F3 Chaib(1994)10 (D)RT-uMLR CK / /Treg CTL / / DspleenDC(R)RT-lDC+ALS (9) NPC+ALS (8)!-TotleMHC total mismatch: n =Monotherapy: n = 3 Combination: n =R-DC:n = 0 D-DC:n =A1: Immature dendritic cells (imDC) group. B1?: Allopeptide-pulsed group. C1?: Gene modification group. D1: Drug intervention group. E1: Mesenchymal stem cell (MSC) induction group. F1?: Other derived group. “ ” Articles did not report the sample size. “/” Articles did not report relevant information. “-” No difference between experiment group and control group. H-2b: C57. H-2d: BAL/C. H-2k: C3H. RT-1u: WF/WAG. RT-1a: ACI. RT-1n: BN. RT-1l: Lewis. D: Donor. R: Recipient. T: The third party. MHC: Major histocompatibility complex. BMDC: Bone marrow dendritic cell. Ag: Antigen. R-KSC: Host kidney-derived MSC. NPCs: Non-parenchymal cells. ALS: Anti-lymphocyte serum. P5: MHC Class I peptide five. 24195657 D-DC: Donor-derived DC. R-DC: Recipient-derived DC. SUR: Survival, “q” Prolongation. MLR: Mixed lymphocyte reaction, “Y” Successfully induced donor specific T cell hyporesponsiveness. CK: Cytokine. CTL: Cytotoxic T lymphocyte, “Y” Reduced cytotoxicity against allografts. Treg: Regulatory T cells, “Y” Successfully induced Treg. doi:10.1371/journal.pon.